agents in the development of cervix carcinoma (2, 3) .
HPV16 transfection of epithelial cells may cause a specific increase in the expression levels of growth factors and their receptors, such as the epidermal growth factor (EGF), leading an enhanced sensitivity to growth stimulation (4, 5) .
Various growth factors can be produced by epithelial cells influencing the neighboring cells and, in some instances, acting as autocrine growth factors, including EGF, nerve growth factor, basic fibroblastic growth factor, tumor growth factor alpha, and endothelin (6 -9) .
The family of endothelins (ETs), named ET-1, ET-2, and ET-3, are 21-amino acid peptides originally identified as potent vasoconstrictors (10) . They act through at least two major receptor subtypes, belonging to the G-protein-coupled family receptors: ET A receptor, which binds ET-1 and ET-2 with high affinity and ET-3 with low affinity; and ET B receptor, which nonselectively binds all ET isopeptides with equal affinity (11) . ET-1 is a potent vasoactive peptide synthesized in vascular endothelial cells and nonvascular tissues. ET-1 acts on cell proliferation directly or synergistically with other growth factors implicated in cancer progression. Several human cancer cells and human tumors release ET-1, and it has been proposed that ET-1 participates in tumor development or progression by exerting autocrine or paracrine action on neoplastic and surrounding stromal cells (12) .
Human keratinocytes express ET A receptors and produce ET-1, which stimulates growth response (9) . Recently, a new mechanism in the growth control of immortalized keratinocytes has been reported. ET-1 is released from HPV transfected keratinocytes and induces increased growth response in these cell lines in comparison with normal cells. All HPV transfected cell lines secrete ET-1 and exhibit a twofold increase in ET A receptors compared to parental cells in the absence of recycling alteration (13) . HPV transfected keratinocytes can proliferate in the absence of any growth factor and their growth is completely prevented by a specific ET A receptor antagonist (14) . These data demonstrate that selective growth of HPV-infected cells is up-regulated by the ET-1 autocrine loop. In the present study, we tested the hypothesis that in HPV-associated cervical cancer cells the expression of ET-1 and its receptors could play a pathophysiological role. Therefore, we evaluated ET-1 production at the mRNA and protein levels and the subtype receptor expression in human normal and cervical cancer cells. New therapeutic strategies against HPV-infected and transformed cells need studies of the inhibition of the autonomous growth of tumor cells. Therefore, we evaluated the receptor subtype mediating the mitogenic effects in the HPV-associated cancer cells and investigated whether specific ET-1 antagonists may inhibit the autocrine growth of cervix cancer cells.
MATERIALS AND METHODS

Cell cultures
Cervical carcinoma derived cell lines, including CaSki, SiHa, and C33A cell lines, were purchased from American Type Culture Collection (Rockville, Md.); HaCaT cells were a gift from L. Laiminis (Chicago). C33A cell lines was maintained in MEM/ 10% fetal calf serum (FCS) and CaSki cells in RPMI/10% FCS. SiHa and HaCaT cells were cultured in DMEM plus 15% or 10% FCS, respectively. All carcinoma cell cultures contained oncogenic HPV DNA with the exception of C33A, which are HPV negative. HaCaT cells are spontaneously growing human keratinocytes that have been used extensively as normal human epithelial cell line (15) .
ET-1 extraction
The conditioned media were acidified with 0.1% trifluoroacetic acid (TFA) and the supernatant was applied to Sep-Pak C18 cartridges. After elution with 2 ml 60% acetonitrile/0.1% TFA, the material was lyophilized and analyzed for ET-1 content by radioimmunoassay (RIA). The recovery of synthetic ET-1 through the extraction procedure was 78%.
Radioimmunoassay
The lyophilized ET-1 samples were reconstituted in the assay solution consisting of 0.1 M phosphate buffer (pH 7.4) containing 0.05 M NaCl, 0.1% bovine serum albumin (BSA), 0.1% Triton-X100, and 0.01% sodium azide. Samples were equilibrated for 24 h at 4°C with specific ET-1 antibody (Peninsula Lab., Belmont, Calif.), followed by the addition of 20,000 cpm of [ 125 I]ET-1 (2200 Ci/mmol; DuPont NEN, Wilmington, Del.). After incubation for additional 48 h, free and antibody-bound tracers were separated by the addition of sheep antiserum to rabbit immunoglobulin and incubated for another 2 h at room temperature. The cross-reactivity of the antiserum for ET-related peptides (vs. ET-1ϭ100%) was ET2 ϭ 7%, ET3 ϭ 7%, and big-ET-1 ϭ 17%. The sensitivity of the ET-1 RIA was 1.9 pg/tube and the 50% intercept was 36 pg/tube. The infra-and interassay variations were 8% and 13%, respectively.
Binding assay
Cells were cultured in 6-well plates until confluent (8ϫ10 5 cells/well) and then growth factors were starved for 24 -48 h. After a wash with the assay buffer composed of Hank's balanced salt solution, 0.2% BSA, and 100 g/ml bacitracin, cells were incubated in 500 l assay buffer containing 40 pM [ Ϫ6 M unlabeled peptide, was 5% of the added radioligand.
RNA extraction and reverse transcriptase-polymerase chain reaction (RT-PCR)
Total RNA was extracted and purified from cell cultures by a commercial kit RNAzol (Biotecx Lab, Houston, Tex.) that uses the guanidinium-thiocyanate method. One microgram of RNA was reverse transcribed to cDNA and amplified by the RNA PCR Kit (Perkin Elmer Co. Oak Brook, Ill.) according to the manufacturer's instructions with the specific primers for GAPDH, ET-1, and ET receptor mRNAs described by Pekonen et al. (16) . Briefly, reverse transcription was carried out at 42°C for 15 min with the downstream primers. Incubation at 99°C for 5 min and then chilling in ice stopped the reaction. The cDNA was amplified with 2.5 U Amplitaq (Roche, Nutley, N.J.) for 30 cycles in the presence of up-and downstream primers. In all experiments two control reactions, one containing no RNA and another containing no reverse transcriptase, were included. The specificity of the amplified products was verified by the presence of products of the expected size and by molecular hybridization with the digoxigenin-labeled internal oligonucleotide probe.
Thymidine incorporation assay
Cells were seeded in 96-well plates (2ϫ10 4 cell/well) and incubated in growth factor-free medium for 24 h. Selected concentrations of ET agonists and/or antagonists (Peninsula Lab.) and EGF (Collaborative Biomedical Products, Bedford, Mass.) were then added; after 18 h, 1 Ci [ 3 H]thymidine (6.7 Ci/ mmol; DuPont, NEN) was added to each well. Six hours later the culture media were removed and cells were washed three times with PBS, fixed with 10% trichloroacetic acid, washed twice with 100% ethanol, and solubilized with 0.4 N NaOH. The cell-associated radioactivity was then determined by liquid scintillation counting.
Growth curve
Cells were seeded in a 96-well plates at a density allowing an exponential growth rate for the following 5 day incubation (2ϫ10 4 cells/well). After overnight incubation, the medium was replaced with a serum-free medium containing the ET-1 antagonists. At 24 h intervals the cellular monolayers were stained with methanol/1% crystal violet. The cell density was evaluated by reading O.D. of the eluted dye at 540 nm. Eight replicas for each point were assayed.
Statistical analysis
All statistical analyses were performed by the IN-STAT software system. The number of binding sites and the K d values were determined by using the LIGAND program.
RESULTS
Production of ir-ET-1 by normal and tumor cervical cell lines
The time course release of immunoreactive ET-1 (ir-ET-1) into the medium was measured in all cell lines examined. The production of ET-1 was detectable as early as 2 h after replacement of the culture medium in all cell lines but the C33A. In this cell line, over a period of 48 h no detectable ET-1 was present in the medium. The ET-1 release increased over a 48 h period for HaCaT and Caski cells, with a maximum of production for tumor cells that was twofold over the normal epithelial HaCaT cells (90 fmol/10 6 cells vs. 40 fmol/10 6 cells at 48 h). The release of ET-1 by SiHa cells was at a lower level and decayed early during the first 10 h (Fig. 1) .
Expression of ET receptors in cervical cancer cells
The ET receptor saturation studies showed that a The values are given as the mean Ϯ sd of three determinations.
b P Ͻ 0.001 respect to HaCaT cell line.
placement capacity of ET-1 compared to ET-3 and S6c, suggesting that the predominant functional receptor in CaSki cells was the ET A subtype (data not shown). 
Expression of mRNA for ET-1 and its receptor subtypes
Proliferative effects of ET-1 in cervical cancer cells
Assays for ET-1-induced mitogenic responses were performed in order to elucidate the role of this peptide in the growth of these tumor cell lines. In all normal and tumoral cervical cell lines, we found that increasing concentrations (1 nM to 100 M) of ET-1 induced a marked dose-dependent increase in [
H]thymidine incorporation in serum-free medium (data not shown). ET-1 was able to induce a marked increase in [
3 H]thymidine incorporation in HPVassociated tumor cell lines compared to the normal cells HaCaT (PϽ0.01) (Fig. 3) . CaSki cells exhibited the highest proliferation rate, apparently reflecting the major number of ET A receptors on the cell surface. To examine whether the mitogenic action of ET-1 was mediated by ET A R, we co incubated the cells with ET-1 and ET A R antagonist BQ123. The stimulatory action of 100 nM ET-1 on [ . Quiescent cells (CaSki, SiHa, HaCaT, and C33A) were incubated with the ET-1 (100 nM) or BQ123 (100 nM), the ET-1 (100 nM) plus the BQ123 (100 nM), ET-3 (100 nM), S6c (100 nM), or EGF (10 ng/ml), or EGF (10 ng/ml) plus BQ123 (100 nM) for 24 h. by the presence of BQ123, suggesting that endogenous ET-1 may act as an autocrine regulator of cell proliferation. In the same experiment, 100 nM of selective ET B agonists ET-3 and S6c had no mitogenic effect. Proliferation of EGF-stimulated cells was not inhibited by BQ123, indicating that the inhibitory effect induced by the ET A receptor antagonist was specific and was not due to cytotoxicity. The inhibitory effect of the ET A R antagonist on ET-1-mediated cell proliferation in the cell lines expressing high-affinity ET receptors, namely, CaSki and SiHa, confirmed that in these cell lines the functional binding site is the ET A receptor. These data were further validated by the stronger stimulating effect of the ET B agonists on C33A cells, which are missing the high-affinity receptor for ET-1. Taken together, these results demonstrate that the mitogenic signaling by ET-1 is mainly mediated by the ET A R subtype in HPV-positive cervical cancer cells.
Growth inhibition by ET A receptor antagonist
In a previous study we demonstrated that human keratinocytes transfected by HPV16 DNA sequences were able to growth in media without any growth factor (13) . To determine whether endogenous ET-1 production by the tumor cells could act as an autocrine growth factor, tumor cells were cultured for up to 4 days in the absence of any growth factor. HaCaT, CaSki, and SiHa cell lines were able to proliferate in growth factor deprivation (data not shown). CaSki cells showed the highest efficiency whereas the C33A failed to growth in these media (Fig. 4) . As shown in Fig. 5 , the spontaneous growth of CaSki cells was significantly and dose-dependently inhibited in the presence of the ET A R antagonist BQ123. The addition of an ET B R antagonist, BQ788, was unable to affect the basal growth rate of the cells although in CaSki cells ET B R mRNA could be detected. These results are consistent with those obtained in the HPV transfected keratinocytes, confirming that the predominant functional receptor present on HPV tumorigenic cervical cells was the ET A R subtype.
DISCUSSION
Growth factors are involved in the development and maintenance of cancer cells. The up-regulation or alteration of their physiological function may lead to an unbalanced growth of the cell (17) . ET-1 is an important growth stimulator in various neoplastic diseases, including breast, ovarian, and prostate cancer (18 -21) . Autocrine ET-1 activity is also involved in the autonomous growth of HPV immortalized keratinocytes (9) . This last finding led us to formulate our hypothesis on the pathophysiological role of ET-1 autocrine loop in HPV-associated cancer.
As postulated for the EGF receptor, the increase of ET-1 receptors enhances the proliferation rate of HPVinfected cells in the presence of a normal amount of growth factor in the microenvironment and could therefore confer a selective advantage to the infected cells (13, 14) . We speculate that in this immortalized population, a second event could account for the generation of tumor cells, suggesting a role for ET-1 in the regulation and promotion of cervical tumor growth. This growth promotion may result from the ability of ET-1 to act alone or with various growth factors, such as EGF, potentiating cellular transformation, and/or proliferation (22) . As a direct consequence of this hypothesis, compounds that antagonize the action of the ET-1 would be able to affect the growth of the HPV-infected or tumor cells. In this study, we first investigated the role of ET-1 in the growth of cervical cancer derived cell lines. Our data indicate that ET-1 is an autocrine/paracrine growth factor for cervical carcinoma cells. This conclusion is based on several observations. All cervical carcinoma cell lines, except C33A, released immunoreactive ET-1 in amounts within the biological range of this peptide. There were differences in the amount and in the timing of production that may reflect differences in the tumor growth activity of these cells or at the least in their ability to proliferate in growth factor-free media. The C33A did not produce ET-1, and therefore the absence of an autocrine loop of ET-1 may explain the lack of growth in media without growth factors. ET-1 mRNA expression confirmed the ET-1 protein production data. The absence of ET-1 mRNA in C33A cells could be mostly accounted for by a block at transcriptional level.
ET-1 possesses at least two different receptors with different affinity for the ET peptides. The binding data clearly demonstrate that these receptors are differently expressed in HPV-positive (CaSki, SiHa) and HPV-negative (C33A) cell lines. High-affinity receptors are mostly present in HPV-positive cancer cells. The functional data recorded by thymidine incorporation assay demonstrate that ET-1 stimulates DNA synthesis in all HPV-associated cervical carcinoma cell lines examined. Moreover, in these cell lines the ET-1 stimulation was higher than in normal HaCaT cells, indicating that ET-1 is able to induce a proliferative advantage in tumor cells. The effect of specific ET A inhibitor or ET B agonists seems to indicate that this growth stimulation is mediated by ET A receptor in HPV-infected cervical cells and by ET B receptor subtype in C33A. Further, the RT-PCR analysis indicates that the functional differences are accounted for the total absence of ET A mRNAs in HPV-negative cervical cancer cells. The highest level of functional ET A receptor expression was detected in CaSki cells, as demonstrated by binding data. In many normal cells, the secretion and action of ET-1 are regulated by the subtype nonselective ET B R, which mediates a variety of compensatory activities including ET-1 clearance, inhibition of ET-1 secretion, and activation of signal transduction pathways that counter-regulate ET-1 (12, 23) . Previous studies have demonstrated a diminished ET B R expression in various tumors (24, 25) . In the present study, competitive binding data revealed that HPV-positive cervical carcinoma cells predominantly express functional ET A R, supporting the hypothesis that the expression and function of ET A R in malignant cervical cells is likely to become the predominant form, representing a relevant mechanisms in tumor proliferation (26) . The endogenous production of ET-1 and the increased number of ET A R may enhance the ability of these cell lines to growth in serum-free media, as demonstrated for HPV transfected keratinocytes (13, 14) . Thus, in the absence of growth factors, the cell lines containing HPV sequences and expressing ET A receptor were able to proliferate with a growth rate that correlates with the number of the ET A binding sites. In particular, CaSki cells, which were the most responsive to the ET-1 action and produced the largest amount of the peptide, showed the highest growth rates. On the contrary, the C33A failed to growth in serum starvation condition, indicating that ET-1 is one of the autocrine growth factors involved in the growth control of HPV-associated cervical cancer cells.
We now hypothesize that the presence of HPV viral sequences may enhance the activity of the ET-1 autocrine loop.
About 90% of the cervical cancers contain DNA sequences of HPV type 16 or 18, and our data indicate that the presence of viral sequence is associated with an active ET-1 autocrine loop. Therefore, the use of a selective ET A antagonist blocking ET-1 effects may result in suppression of tumor growth and of progression of the HPV-associated cancer. In our experiments, the presence of a specific antagonist of the ET A receptor, BQ 123, dramatically inhibited the growth of CaSki cells. The inhibition of the growth is dose-dependent; moreover, BQ788, an ET B antagonist, failed to affect the cell growth, confirming that the ET-1/ET A loop is one of the drivers of tumor growth. The activity of ET-1 and the inhibitory effect of an ET A receptor antagonist on HPV-associated carcinoma cell proliferation indicate that the up-regulation of ET-1 autocrine loop might provide a selective growth advantage for HPV-associated tumor cells. Early clinical trials using specific antagonist for ET A R suggest the potential to treat cancer patients (27) .
Taken together, these findings not only support a role for ET-1 in the HPV-associated cancer, but also provide a therapeutic target for endothelin receptor blockade in the treatment of cervical carcinoma.
